BioCentury
ARTICLE | Clinical News

Alagebrium: Completed Phase II enrollment

January 19, 2009 8:00 AM UTC

Synvista completed enrollment of 102 patients in the double-blind, placebo-controlled, Dutch Phase II BENEFICIAL trial evaluating 200 mg of oral alagebrium given twice daily for 9 months. ...